Nebulized liposomal amphotericin B and combined systemic antifungal therapy for the treatment of severe pulmonary aspergillosis after allogeneic hematopoietic stem cell transplant for a fatal mitochondrial disorder.
J Chemother
; 19(3): 339-42, 2007 Jun.
Article
em En
| MEDLINE
| ID: mdl-17594932
ABSTRACT
Nebulized liposomal amphotericin B (20-15 mg twice daily by nebulizer) was combined with high dose intravenous liposomal amphotericin B (10 mg/kg/day) and high dose caspofungin (100 mg/m(2)) for the treatment of severe, recurrent pulmonary aspergillosis following allogeneic hematopoietic stem cell transplantation from alternative donor in a patient with mitochondrial disease (Pearson's syndrome). This combined treatment was administered for 8 days. Nebulized liposomal amphotericin B was well tolerated. Since severe transplant complications developed, nebulized administration was withdrawn and intravenous doses of liposomal amphotericin B and caspofungin were tapered to usual schedules. Pulmonary aspergillosis responded well to 45 days of combined intravenous antifungal therapies which were maintained for 2 years with secondary prophylaxis, because of persistent immunosuppressive treatment.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fosfatidilcolinas
/
Fosfatidilgliceróis
/
Aspergilose
/
Anfotericina B
/
Transplante de Células-Tronco Hematopoéticas
/
Doenças Mitocondriais
/
Pneumopatias Fúngicas
/
Antifúngicos
Limite:
Female
/
Humans
Idioma:
En
Revista:
J Chemother
Ano de publicação:
2007
Tipo de documento:
Article